Home Markets TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein...

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30) pipeline Market Research Report 2017

84
SHARE

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30) Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Involved in TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30) Development are Eli Lilly and Company, SK Chemicals Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Takeda Pharmaceutical Company Ltd, Yuhan Corp

The TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30) pipeline guide also reviews of key players involved in therapeutic development for TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5 and 1 respectively.

Sample copy is available at https://www.marketinsightsreports.com/reports/062215760/tgf-beta-receptor-type-1-activin-a-receptor-type-ii-like-protein-kinase-of-53kd-or-activin-receptor-like-kinase-5-or-serine-threonine-protein-kinase-receptor-r4-or-transforming-growth-factor-beta-receptor-type-i-or-alk5-or-tgfbr1-or-ec-2-7-11-30-pipeline-review-h1-2017/inquiry

Scope of this report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30). The pipeline guide reviews pipeline therapeutics for TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30).
  • This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30). Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD Or Activin Receptor Like Kinase 5 Or Serine/Threonine Protein Kinase Receptor R4 Or Transforming Growth Factor Beta Receptor Type I Or ALK5 Or TGFBR1 Or EC 2.7.11.30) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report at: https://www.marketinsightsreports.com/reports/062215760/tgf-beta-receptor-type-1-activin-a-receptor-type-ii-like-protein-kinase-of-53kd-or-activin-receptor-like-kinase-5-or-serine-threonine-protein-kinase-receptor-r4-or-transforming-growth-factor-beta-receptor-type-i-or-alk5-or-tgfbr1-or-ec-2-7-11-30-pipeline-review-h1-2017

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report TGF Beta Receptor Type 1 – Pipeline Review, H1 2017, outlays comprehensive information on the TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) – Transforming growth factor beta receptor I is a TGF beta receptor encoded by TGFBR1 gene. It is involved in physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Musculoskeletal Disorders, Oncology, Dermatology, Central Nervous System, Genito Urinary System And Sex Hormones, Immunology, Respiratory, Toxicology and Undisclosed which include indications Hepatocellular Carcinoma, Inflammatory Bowel Disease, Liver Fibrosis, Myelodysplastic Syndrome, Solid Tumor, Alzheimer’s Disease, Androgenic Alopecia, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Degenerative Disc Disease, Fibrosis, Glioblastoma Multiforme (GBM), Inflammation, Kidney Fibrosis, Malignant Glioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Non-Small Cell Lung Cancer, Oral Mucositis, Osteoarthritis, Prostate Cancer, Pulmonary Fibrosis, Radiodermatitis, Recurrent Glioblastoma Multiforme (GBM), Scar, Unspecified and Wounds.

Furthermore, this report also reviews key players involved in TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

LEAVE A REPLY

Please enter your comment!
Please enter your name here